Recombinant Mycoplasma pneumoniae Uncharacterized protein MG263 homolog (MPN_381)

What is MPN_381 and how does it relate to MG263 in Mycoplasma genitalium?

MPN_381 is an uncharacterized protein in Mycoplasma pneumoniae that shares sequence homology with the MG263 protein in Mycoplasma genitalium. MG263 is annotated as a putative phosphatase in Mycoplasma genitalium, suggesting that MPN_381 may have similar enzymatic functions . The relationship between these proteins reflects the evolutionary connection between these two closely related Mycoplasma species, which share many orthologous genes with varying degrees of sequence similarity. Similar to other characterized Mycoplasma protein pairs like MPN387 and MG_269, which show considerable sequence identity and similarity, MPN_381 and MG263 likely maintain conserved functional domains while potentially having species-specific adaptations.

What computational methods can I use to predict MPN_381 structure and function?

Several computational approaches can help predict the structure and function of MPN_381:

• Homology modeling: Using comparative modeling tools like those available through SSGCID, which have successfully modeled other Mycoplasma proteins .

• Coiled-coil prediction: Tools like COILS can identify potential structural motifs, as was done for MPN387 where residues 72-290 were predicted to form a coiled-coil region .

• Sequence alignment: Comparing MPN_381 with MG263 and other putative phosphatases to identify conserved catalytic residues.

• Domain prediction: Tools like InterPro or Pfam can identify conserved domains that might suggest function.

For example, the analysis of the MPN387 amino acid sequence using COILS revealed a coiled-coil region spanning residues 72 to 290 with a predicted length of 31.9 nm . Similar analysis could provide initial structural insights into MPN_381.

How can I verify if MPN_381 is truly a homolog of MG263?

To verify homology between MPN_381 and MG263, implement the following methodological approach:

• Database searches: Search HomoloGene with the gene name and organism (e.g., "MG263[gene name] AND mycoplasma genitalium[orgn]") .

• Sequence alignment: Perform pairwise alignment between MPN_381 and MG263 to calculate sequence identity and similarity percentages.

• Phylogenetic analysis: Construct a phylogenetic tree including MPN_381, MG263, and related proteins from other species.

• Functional complementation: Express MPN_381 in a MG263 knockout strain of M. genitalium to test for functional complementation.

• Structural comparison: If structural data becomes available, compare the three-dimensional structures of both proteins.

When researchers compared MPN387 with its ortholog MG_269, they identified 175 identical and 39 similar amino acid residues out of total sequences of 358 and 340 residues, respectively . A similar approach would be valuable for MPN_381 and MG263.

What expression systems are most suitable for recombinant production of MPN_381?

Based on successful expression strategies for other Mycoplasma proteins, the following systems are recommended:

For MPN387, researchers successfully used E. coli BL21(DE3) pLysS with a pET15b vector, resulting in over 70% solubility of the recombinant protein, which yielded 1.5 mg of purified protein per liter of culture . This system would be a logical starting point for MPN_381 expression.

How can I optimize protein yields when expressing recombinant MPN_381?

To optimize expression yields of recombinant MPN_381, consider these methodological parameters:

• Induction conditions: For MPN387, induction was performed at OD600 of 0.5 with 0.1 mM IPTG, followed by 3 hours of expression at 30°C . Test multiple combinations of IPTG concentration (0.1-1.0 mM), induction temperature (16-37°C), and induction duration (3-24 hours).

• Media optimization: Compare rich media (LB) with auto-induction media or defined media supplemented with glucose and specific amino acids.

• Codon optimization: Optimize the MPN_381 sequence for E. coli codon usage, particularly if expression levels are low.

• Fusion tags: Test multiple constructs with different tags (His, GST, MBP, SUMO) at both N- and C-termini to identify the most soluble variant.

• Cell lysis conditions: Optimize buffer components including salt concentration, pH, and presence of stabilizing agents like glycerol.

What purification strategy should I implement for MPN_381?

A multi-step purification strategy is recommended for obtaining high-purity MPN_381:

• Initial capture: Immobilized metal affinity chromatography (IMAC) using Ni-NTA resin for His-tagged protein.

• Intermediate purification: Ion exchange chromatography based on the predicted isoelectric point of MPN_381.

• Polishing step: Size exclusion chromatography to separate oligomeric forms and remove aggregates.

• Tag removal: If necessary for functional studies, remove the His-tag using thrombin or another appropriate protease.

• Quality control: Assess purity by SDS-PAGE and verify identity by Western blot and mass spectrometry.

For MPN387, researchers used Ni-NTA affinity chromatography followed by gel filtration chromatography, which proved effective in isolating the protein with high purity as confirmed by SDS-PAGE analysis .

What techniques are most informative for structural characterization of MPN_381?

A comprehensive structural characterization of MPN_381 should employ multiple complementary techniques:

In the case of MPN387, researchers successfully employed CD spectroscopy, gel filtration chromatography, analytical ultracentrifugation, electron microscopy, and partial proteolysis to characterize its dumbbell-shaped homodimeric structure with dimensions of approximately 42.7 nm in length and 9.1 nm in diameter .

How should I design constructs for structural studies of MPN_381?

Strategic construct design is critical for successful structural studies:

• Domain prediction: Use bioinformatics to identify potential domains, flexible regions, and structured core.

• Multiple constructs: Design a panel of constructs with different boundaries to increase chances of crystallization.

• Surface entropy reduction: Identify and mutate surface residue clusters with high conformational entropy.

• Fusion partners: Consider crystallization chaperones like T4 lysozyme or BRIL for challenging proteins.

• Tag position optimization: Test both N- and C-terminal tags, with appropriate linkers and protease cleavage sites.

For fluorescent protein tagging experiments similar to those performed with MPN387, designing constructs with mEYFP fusion at either the N-terminus or C-terminus can help with localization studies while maintaining protein solubility .

What approaches can resolve contradictory structural data for MPN_381?

When faced with contradictory structural data, implement this systematic resolution approach:

• Verify protein integrity: Confirm that all experiments used properly folded, non-degraded protein by mass spectrometry and SDS-PAGE.

• Consider environmental factors: Evaluate how buffer conditions, pH, temperature, and ionic strength affect structure.

• Oligomeric state assessment: Determine if different techniques are capturing different oligomeric forms.

• Complementary methods: Employ orthogonal techniques that provide different structural information.

• Computational validation: Use molecular dynamics simulations to test the stability of proposed structural models.

• Functional correlation: Test which structural model best explains functional data.

What assays can effectively characterize the putative phosphatase activity of MPN_381?

To characterize the putative phosphatase activity of MPN_381, implement these methodological approaches:

• Colorimetric assays: Use p-nitrophenyl phosphate (pNPP) as a substrate and measure absorbance at 405 nm to quantify phosphate release.

• Malachite green assay: Measure inorganic phosphate released from natural substrates like phosphorylated peptides.

• Phospho-specific antibodies: Use Western blotting to monitor dephosphorylation of specific protein substrates.

• Mass spectrometry: Identify specific phosphorylation sites on substrate proteins before and after treatment with MPN_381.

• Kinetic analysis: Determine Km, Vmax, and catalytic efficiency using various substrates.

For each assay, include appropriate controls:

• Enzyme-only control

• Substrate-only control

• Known phosphatase (positive control)

• Heat-inactivated MPN_381 (negative control)

• Phosphatase inhibitors to confirm specificity

How can I identify physiological substrates and interaction partners of MPN_381?

To identify the physiological role of MPN_381, employ these substrate identification approaches:

• Protein microarrays: Screen arrays of phosphorylated proteins for dephosphorylation by MPN_381.

• Affinity purification-mass spectrometry: Use tagged MPN_381 to pull down interacting proteins from M. pneumoniae lysates.

• Yeast two-hybrid screening: Identify potential protein-protein interactions.

• Co-immunoprecipitation: Validate specific interactions in vivo.

• Phosphoproteomics: Compare the phosphoproteome of wild-type and MPN_381 knockout strains.

• Biolayer interferometry or surface plasmon resonance: Measure binding kinetics with candidate substrates.

What role might MPN_381 play in Mycoplasma pneumoniae pathogenesis?

While specific information about MPN_381's role in pathogenesis is limited, several experimental approaches can help elucidate its function:

• Gene knockout studies: Generate MPN_381 deletion mutants and assess changes in:

  • Adhesion to host cells

  • Gliding motility

  • Cytotoxicity

  • Inflammatory response induction

• Location determination: Similar to studies with MPN387, use fluorescent protein tagging to determine subcellular localization .

• Temporal expression analysis: Monitor expression during different stages of infection.

• Host interaction studies: Investigate if MPN_381 directly interacts with host cell components.

If MPN_381 functions similarly to other characterized Mycoplasma proteins like MPN387, it may play a role in essential cellular processes. MPN387, for example, is a component of the bowl complex and is essential for gliding motility but dispensable for cytadherence , suggesting specialized functional roles for these proteins.

What experimental research design is most appropriate for studying MPN_381 function?

When designing experiments to study MPN_381 function, consider these research design approaches:

• True experimental design: This approach allows for establishing cause-effect relationships through:

  • Control groups (e.g., wild-type M. pneumoniae)

  • Experimental groups (e.g., MPN_381 knockout or overexpression strains)

  • Randomly distributed variables

  • Manipulation of independent variables

• Pre-experimental studies: Before conducting extensive experiments, perform preliminary studies to:

  • Establish baseline expression levels

  • Determine optimal conditions for protein activity

  • Identify potential functional readouts

• Quasi-experimental design: When random assignment is not possible:

  • Compare clinical isolates with varying MPN_381 expression

  • Study natural variants of MPN_381 in different strains

For each experimental approach, document:

• Clear hypotheses

• Independent and dependent variables

• Control measures

• Statistical analysis plan

• Expected outcomes and alternative interpretations

How should I design controls for phosphatase activity assays?

A robust experimental design for phosphatase activity assays should include these controls:

• Positive controls:

  • Commercial phosphatases of known activity

  • Well-characterized bacterial phosphatases

  • Alkaline phosphatase from calf intestine

• Negative controls:

  • Buffer-only reactions

  • Heat-denatured MPN_381

  • MPN_381 with site-directed mutations in predicted catalytic residues

  • MPN_381 treated with specific phosphatase inhibitors

• Substrate controls:

  • Non-hydrolyzable phosphate analogs

  • Pre-dephosphorylated substrates

  • Varying concentrations of substrate to determine enzyme kinetics

• Specificity controls:

  • Panel of different phosphorylated substrates

  • Varying pH, metal ion, and buffer conditions

How do I interpret contradictory results from different functional assays?

When faced with contradicting functional data, implement this systematic troubleshooting approach:

• Verify protein quality:

  • Check for degradation by SDS-PAGE

  • Confirm proper folding by circular dichroism

  • Validate activity of known controls

• Evaluate assay conditions:

  • Test multiple buffer systems

  • Vary pH, temperature, and ionic strength

  • Assess metal ion dependence

• Consider protein modifications:

  • Test both tagged and untagged versions

  • Evaluate different expression systems

  • Check for post-translational modifications

• Assay interference:

  • Look for components that might inhibit activity

  • Test for interfering substances in protein preparations

  • Evaluate potential substrate/product inhibition

• Biological context:

  • Consider if MPN_381 requires cofactors or partner proteins

  • Test activity in cellular extracts versus purified systems

How can structural information about MPN_381 inform drug discovery efforts?

Structural information about MPN_381 can drive drug discovery through these approaches:

• Structure-based virtual screening:

  • Identify potential binding pockets in the MPN_381 structure

  • Screen virtual libraries for compounds that dock to these sites

  • Rank compounds based on predicted binding energy

• Fragment-based drug design:

  • Screen fragment libraries for weak binders to MPN_381

  • Link or grow fragments to improve potency

  • Optimize lead compounds based on structure-activity relationships

• Peptide inhibitor design:

  • Identify interaction surfaces with binding partners

  • Design peptides that mimic these interfaces

  • Develop stapled peptides for improved stability

• Allosteric modulator development:

  • Identify allosteric sites that affect enzyme activity

  • Design molecules that stabilize inactive conformations

  • Target unique structural features not present in human homologs

What approaches can determine if MPN_381 contributes to antibiotic resistance?

To investigate potential roles of MPN_381 in antibiotic resistance:

• Expression correlation studies:

  • Compare MPN_381 expression levels in sensitive versus resistant strains

  • Monitor expression changes upon antibiotic exposure

• Gene knockout/overexpression:

  • Determine if MPN_381 deletion affects antibiotic susceptibility

  • Test if overexpression confers resistance

• Interaction studies:

  • Investigate direct interactions between MPN_381 and antibiotics

  • Study potential enzymatic modification of antibiotics

• Structural analysis:

  • Look for structural similarities to known resistance proteins

  • Identify potential antibiotic binding sites

• Phosphorylation studies:

  • Determine if MPN_381 phosphatase activity affects antibiotic target proteins

  • Investigate phosphorylation-dependent resistance mechanisms

How could MPN_381 be utilized in diagnostic applications for Mycoplasma pneumoniae infection?

Several approaches could leverage MPN_381 for improved M. pneumoniae diagnostics:

• Serological detection:

  • Develop antibody-based assays targeting MPN_381

  • Evaluate sensitivity/specificity compared to current tests

  • Design multiplex assays including MPN_381 and other biomarkers

• Molecular diagnostics:

  • Design PCR primers specific to the MPN_381 gene

  • Develop LAMP or other isothermal amplification assays

  • Create hybridization probes for microarray detection

• Activity-based probes:

  • Design probes that react with MPN_381 phosphatase activity

  • Develop activity-based assays for viable bacteria detection

• Point-of-care applications:

  • Incorporate anti-MPN_381 antibodies into lateral flow assays

  • Develop biosensors based on MPN_381 detection

  • Create microfluidic devices for automated detection

• Strain typing:

  • Identify strain-specific variants of MPN_381

  • Develop assays to differentiate clinically relevant strains

  • Create databases of MPN_381 sequence variations